Testing HP-002 for returning or treatment-resistant B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies HP-002, a new drug, for people with certain types of B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. HP-002 works differently than standard therapies, so it may help when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell non-Hodgkin lymphoma (including CLL, SLL, MCL, MZL, DLBCL, FL, Waldenstrom's macroglobulinemia, or brain lymphoma) that has returned or is not responding to treatment.
- You must be able to take care of yourself and be up and about at least half of your waking hours (ECOG performance status 0-2).
- You must not have used a BTK protein degrader drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This early-stage trial tests a new cell therapy called GI001 for patients with B-cell lymphomas or leukemias that have come back or stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells.
This trial tests an investigational cell therapy called B019 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The therapy targets cancer cells that have CD19 and/or CD22 on their surface, and the study aims to see if it is safe and effective.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.